van Pesch V - Search Results

1

Prophylactic treatment against GM-CSF, but not IL-17, abolishes relapses in a chronic murine model of multiple sclerosis.

Uyttenhove C, Gaignage M, Donckers D, Nasr Z, Cheou P, van Snick J, D'Auria L, van Pesch V. Uyttenhove C, et al. Among authors: van snick j, van pesch v. Eur J Immunol. 2018 Nov;48(11):1883-1891. doi: 10.1002/eji.201847580. Epub 2018 Sep 25. Eur J Immunol. 2018. PMID: 30216414 Free article.

2

Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network.

Muls N, Jnaoui K, Dang HA, Wauters A, Van Snick J, Sindic CJ, van Pesch V. Muls N, et al. Among authors: van snick j, van pesch v. J Neuroimmunol. 2012 Feb 29;243(1-2):73-80. doi: 10.1016/j.jneuroim.2011.12.010. Epub 2012 Jan 14. J Neuroimmunol. 2012. PMID: 22245284

3

'Hidden' factors influencing quality of life in patients with multiple sclerosis.

Lysandropoulos AP, Havrdova E; ParadigMS Group. Lysandropoulos AP, et al. Eur J Neurol. 2015 Oct;22 Suppl 2:28-33. doi: 10.1111/ene.12801. Eur J Neurol. 2015. PMID: 26374511 Review.

4

IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy.

Muls N, Nasr Z, Dang HA, Sindic C, van Pesch V. Muls N, et al. Among authors: van pesch v. PLoS One. 2017 Mar 16;12(3):e0173780. doi: 10.1371/journal.pone.0173780. eCollection 2017. PLoS One. 2017. PMID: 28301515 Free PMC article.

5

CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders.

Perdaens O, Dang HA, D'Auria L, van Pesch V. Perdaens O, et al. Among authors: van pesch v. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 7;7(2):e673. doi: 10.1212/NXI.0000000000000673. Print 2020 Mar 5. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32033981 Free PMC article.

6

Mechanism of Cellular Formation and In Vivo Seeding Effects of Hexameric β-Amyloid Assemblies.

Vrancx C, Vadukul DM, Suelves N, Contino S, D'Auria L, Perrin F, van Pesch V, Hanseeuw B, Quinton L, Kienlen-Campard P. Vrancx C, et al. Among authors: van pesch v. Mol Neurobiol. 2021 Dec;58(12):6647-6669. doi: 10.1007/s12035-021-02567-8. Epub 2021 Oct 4. Mol Neurobiol. 2021. PMID: 34608607 Free PMC article.

7

Recurrent Miller Fisher syndrome with vestibular involvement.

Vermeersch G, Boschi A, Deggouj N, van Pesch V, Sindic CJ. Vermeersch G, et al. Among authors: van pesch v. Eur Neurol. 2011;66(4):210-4. doi: 10.1159/000331486. Epub 2011 Sep 21. Eur Neurol. 2011. PMID: 21934313

8

Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.

Muls N, Dang HA, Sindic CJ, van Pesch V. Muls N, et al. Among authors: van pesch v. PLoS One. 2014 Nov 20;9(11):e113025. doi: 10.1371/journal.pone.0113025. eCollection 2014. PLoS One. 2014. PMID: 25411844 Free PMC article.

9

Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse.

Muls NG, Dang HA, Sindic CJ, van Pesch V. Muls NG, et al. Among authors: van pesch v. Mult Scler. 2015 Oct;21(12):1533-45. doi: 10.1177/1352458514567215. Epub 2015 Feb 6. Mult Scler. 2015. PMID: 25662347

10

Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.

Kroksveen AC, Jaffe JD, Aasebø E, Barsnes H, Bjørlykke Y, Franciotta D, Keshishian H, Myhr KM, Opsahl JA, van Pesch V, Teunissen CE, Torkildsen Ø, Ulvik RJ, Vethe H, Carr SA, Berven FS. Kroksveen AC, et al. Among authors: van pesch v. Proteomics. 2015 Oct;15(19):3361-9. doi: 10.1002/pmic.201400142. Epub 2015 Sep 8. Proteomics. 2015. PMID: 26152395

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209 results

Search Page

Filters